-
Home
-
Media and Information
- Press Releases
Press Releases
- Details
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring International Plasma Awareness Week, October 13-20, designed to:
- Details
Brussels, Belgium—The Plasma Protein Therapeutics Association (PPTA), together with Pharmig and IG Plasma are sponsoring a workshop as part of International Plasma Awareness Week, October 13-20. This event is a joint initiative of PPTA and its member companies designed to:
- Details
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring International Plasma Awareness Week, October 13-20. This inaugural event is designed to:
- Details
Annapolis, MD--The first ever International Plasma Awareness Week (IPAW) will be celebrated October 13-20. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:
- Details
Mary Gustafson, PPTA Vice President, Global Regulatory Policy, was honored on July 24 with the 2013 FDA Distinguished Alumni Award at the FDA Honor Awards Ceremony, “for exceptional contributions to the regulation of blood and blood products, and as an outstanding liaison between FDA and the plasma protein industry.”
- Details
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) opposes New Jersey Senate Bill 2132 that imposes a new tax on therapies used to treat bleeding disorders such as hemophilia.
- Details
The Plasma Protein Therapeutics Association is pleased to announce substantive improvements to its Quality Standards for Excellence and Leadership (QSEAL)
- Details
The 2013 Plasma Protein Forum was held in Reston, Virginia on June 11-12.
- Details
The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.
- Details
The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency disease (PID) community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PID.
Media and Information
PPTA News
-
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans” +
The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.
Read More -
Highlights from the 2018 IPPC +
Mr. Jan M. Bult, President & CEO, PPTA, opened the well-attended IPPC 2018 by welcoming the more than 300 attendees to Budapest. PPTA thanks its sponsors who help make the IPPC possible every year. Download the IPPC app (available in the Apple AppStore and Android Market/Google Play) for Apple or Android devices) for a complete list of sessions and many of the presentations.
Read More -
GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS +
“How Is Your Day?” highlights value of plasma protein therapies in improving patients’ lives
Budapest, HUNGARY (March 13)– The Plasma Protein Therapeutics Association (PPTA) today unveiled its new global initiative, “How Is Your Day?” –Making the difference with plasma proteins, in conjunction with the annual International Plasma Protein Congress. “How Is Your Day?” will focus on differentiating these unique therapies from traditional pharmaceuticals and building awareness of the value they provide for people living with rare, life-threatening, chronic, and genetic diseases.
Read More
- 1
- 2
- 3
The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.
Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.